社交恢复治疗联合早期干预服务促进首发精神病患者社交康复(SUPEREDEN3)
SUPEREDEN3 是一项在英国四个专科早期干预服务中心开展的单盲、2 期随机对照试验,纳入 155 名 16-35 岁、非情感性精神病、接受早期干预服务 12-30 个月且存在持续严重社交失能(每周结构化活动少于 30 小时)的患者。患者按 1:1 随机分配接受社交恢复治疗联合早期干预服务或单纯早期干预服务,主要结局为 9 个月时通过 Time Use Survey 测量的结构化活动时间。
要点
- 对早期干预服务中仍存在持续严重社交失能的首发精神病患者,联合社交恢复治疗可增加 9 个月时的结构化活动时间。
- 未发现归因于研究治疗的不良事件,提示该联合干预在该人群中具有可接受的安全性。
核心结论
- 在首发精神病且接受早期干预服务后仍存在持续严重社交失能的患者中,社交恢复治疗联合早期干预服务较单纯早期干预服务改善 9 个月时的结构化活动。
- 联合干预可能对改善首发精神病患者的功能结局有用,尤其适用于缺乏动机参与现有针对功能的社会心理干预或存在妨碍参与共病问题者。
研究设计与样本
- 单盲、2 期随机对照试验(SUPEREDEN3),在英国四个专科早期干预服务中心开展。
- 纳入 16-35 岁、非情感性精神病、接受早期干预服务 12-30 个月且每周结构化活动少于 30 小时的患者。
- 按 1:1 计算机生成随机化(区组大小 4-6)分配至社交恢复治疗联合早期干预服务组(n=76)或单纯早期干预服务组(n=79),按性别和招募中心分层。
- 意向治疗人群 154 例;9 个月时 143 例(93%)有主要结局数据;结局评估者设盲。
- 试验注册号 ISRCTN61621571。
主要发现
- 未发现归因于研究治疗的不良事件。
关键数值与推荐
- 主要结局为 9 个月时 Time Use Survey 测量的结构化活动时间。
- 纳入标准包括每周结构化活动少于 30 小时。
- 接受早期干预服务时间为 12-30 个月。
临床怎么用
- 对接受早期干预服务 12-30 个月后仍存在持续严重社交失能的首发精神病患者,可考虑在早期干预服务基础上联合社交恢复治疗。
- 联合干预可能尤其适用于缺乏动机参与现有针对功能的社会心理干预或存在妨碍参与共病问题者。
局限性
- 参与者因干预性质无法对分组设盲。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Provision of early intervention services has increased the rate of social recovery in patients with first-episode psychosis; however, many individuals have continuing severe and persistent problems with social functioning. We aimed to assess the efficacy of early intervention services augmented with social recovery therapy in patients with first-episode psychosis. The primary hypothesis was that social recovery therapy plus early intervention services would lead to improvements in social recovery. METHODS: We did this single-blind, phase 2, randomised controlled trial (SUPEREDEN3) at four specialist early intervention services in the UK. We included participants who were aged 16-35 years, had non-affective psychosis, had been clients of early intervention services for 12-30 months, and had persistent and severe social disability, defined as engagement in less than 30 h per week of structured activity. Participants were randomly assigned (1:1), via computer-generated randomisation with permuted blocks (sizes of four to six), to receive social recovery therapy plus early intervention services or early intervention services alone. Randomisation was stratified by sex and recruitment centre (Norfolk, Birmingham, Lancashire, and Sussex). By necessity, participants were not masked to group allocation, but allocation was concealed from outcome assessors. The primary outcome was time spent in structured activity at 9 months, as measured by the Time Use Survey. Analysis was by intention to treat. This trial is registered with ISRCTN, number ISRCTN61621571. FINDINGS: Between Oct 1, 2012, and June 20, 2014, we randomly assigned 155 participants to receive social recovery therapy plus early intervention services (n=76) or early intervention services alone (n=79); the intention-to-treat population comprised 154 patients. At 9 months, 143 (93%) participants had data for the primary outcome. Social recovery therapy plus early intervention services was associated with an increase in structured activity of 8·1 h (95% CI 2·5-13·6; p=0·0050) compared with early intervention services alone. No adverse events were deemed attributable to study therapy. INTERPRETATION: Our findings show a clinically important benefit of enhanced social recovery on structured activity in patients with first-episode psychosis who received social recovery therapy plus early intervention services. Social recovery therapy might be useful in improving functional outcomes in people with first-episode psychosis, particularly in individuals not motivated to engage in existing psychosocial interventions targeting functioning, or who have comorbid difficulties preventing them from doing so. FUNDING: National Institute for Health Research.
引用
- Fowler D, Hodgekins J, French P, et al. Social recovery therapy in combination with early intervention services for enhancement of social recovery in patients with first-episode psychosis (SUPEREDEN3): a single-blind, randomised controlled trial. Lancet Psychiatry. 2017. PMID: 29242000. doi:10.1016/S2215-0366(17)30476-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。